or Try an Advanced Search...

    Technical Analysis for ALXO - ALX Oncology Holdings Inc.

    Grade Last Price % Change Price Change
    A 16.86 -0.06% -0.01
    ALXO closed down 0.06 percent on Friday, April 26, 2024, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    Earnings due: May 9
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical ALXO trend table...
    Date Alert Name Type % Chg
    Doji - Bearish? Reversal 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    New 52 Week Closing High Bullish -0.06%
    Stochastic Reached Overbought Strength -0.06%
    Wide Bands Range Expansion -0.06%
    Overbought Stochastic Strength -0.06%
    Up 3 Days in a Row Strength -0.06%
    Wide Bands Range Expansion 3.95%
    180 Bullish Setup Bullish Swing Setup 8.77%
    Older End-of-Day Signals for ALXO ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown 1 day ago
    Down 1% 1 day ago
    Rose Above Previous Day's High 2 days ago
    Up 2% 2 days ago
    Up 1% 2 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ALXO Chart by TradingView
    Basic chart:

    Profile

    ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Cancer Immunotherapy Acute Myeloid Leukemia Epidermal Growth Factor Receptor Carcinoma Myelodysplastic Syndrome Syndromes Treatment Of Myelodysplastic Syndrome

    Is ALXO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 24 ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
    Apr 18 ALX Oncology: Trying To Justify The Hype
    Apr 15 Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
    Apr 11 ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
    Apr 9 ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
    Apr 6 ALX Oncology Holdings Inc (ALXO) Insider Sells Shares
    Mar 10 Cantor sees strong year ahead for oncology M&A
    Mar 8 Stifel downgrades ALX Oncology to hold, sees evorpacept as fully valued
    Mar 8 ALX Oncology Has 'Elevated Valuation' - Analyst Downgrades Stock, Highlights Need For Development De-Risking Beyond Gastric Cancer
    Mar 8 ALX Oncology Holdings Inc (ALXO) Reports Growth Amidst Increased R&D Spending
    See more ALXO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.42
    52 Week Low 3.9357
    Average Volume 520,444
    200-Day Moving Average 10.11
    50-Day Moving Average 13.74
    20-Day Moving Average 13.67
    10-Day Moving Average 15.45
    Average True Range 1.16
    RSI (14) 66.89
    ADX 27.99
    +DI 35.01
    -DI 14.82
    Chandelier Exit (Long, 3 ATRs) 13.90
    Chandelier Exit (Short, 3 ATRs) 13.96
    Upper Bollinger Bands 17.79
    Lower Bollinger Band 9.55
    Percent B (%b) 0.89
    BandWidth 60.26
    MACD Line 1.01
    MACD Signal Line 0.59
    MACD Histogram 0.4263
    Fundamentals Value
    Market Cap 839.94 Million
    Num Shares 49.8 Million
    EPS -3.57
    Price-to-Earnings (P/E) Ratio -4.72
    Price-to-Sales 5906.24
    Price-to-Book 4.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 18.11
    Resistance 3 (R3) 18.14 17.75 17.90
    Resistance 2 (R2) 17.75 17.44 17.74 17.83
    Resistance 1 (R1) 17.31 17.24 17.53 17.28 17.76
    Pivot Point 16.92 16.92 17.04 16.91 16.92
    Support 1 (S1) 16.48 16.61 16.70 16.45 15.96
    Support 2 (S2) 16.09 16.41 16.08 15.89
    Support 3 (S3) 15.65 16.09 15.82
    Support 4 (S4) 15.62